SDC antimicrobial company PURE Bioscience Inc (OTCQB:PURE) stated on Friday that it recorded a net loss of USD1.1m (net loss of USD0.01 per share) for the fiscal first quarter ended 31 October 2019.

This marks a rise in earnings when compared with net loss of USD2.6m (net loss of USD0.04 per share) for the fiscal first quarter in 2019.

Revenues of USD398,000 were generated for the fiscal first quarter ended 31 October 2019, down 33% over the prior fiscal first quarter revenues of USD590,000, which was primarily attributable to a reduction in sales of the raw material ingredient, SILVÉRION.

Gross margin was 61% in the fiscal first quarter 2020 versus 66% in the same period in fiscal 2019, which was attributable to the sale of lower margin formulations and packaging configurations during the quarter ended 31 October 2019 as compared with the same period in fiscal 2019.